Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Increases By 37.4%

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 89,300 shares, a growth of 37.4% from the November 30th total of 65,000 shares. Currently, 6.2% of the company’s stock are short sold. Based on an average daily volume of 1,230,000 shares, the days-to-cover ratio is currently 0.1 days.

Tharimmune Stock Performance

Tharimmune stock traded down $0.09 during midday trading on Friday, reaching $2.06. The company’s stock had a trading volume of 144,086 shares, compared to its average volume of 348,641. Tharimmune has a 52 week low of $1.84 and a 52 week high of $8.42. The business has a 50-day moving average price of $2.29 and a 200-day moving average price of $2.72.

Analyst Ratings Changes

A number of brokerages have recently commented on THAR. Rodman & Renshaw began coverage on shares of Tharimmune in a research report on Friday, December 6th. They issued a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a report on Friday, December 6th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC purchased a new stake in Tharimmune, Inc. (NASDAQ:THAR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.16% of the company’s stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).